EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity

Angelo Avogaro iD

European Journal of Clinical Investigation · 2026

DOI: 10.1111/eci.70184 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von Angelo Avogaro. Beteiligte Einrichtung: School of Medicine, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Incretins, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 126 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes mellitus is a leading global health concern. The parallel rise in obesity has exacerbated this burden, with projections suggesting over half of the adult population will be overweight or obese by 2050. Incretin‐based therapies have emerged as cornerstone treatments for type 2 diabetes (T2DM), offering glycemic control alongside promising cardiovascular and renal benefits.

Results

This review consolidates current evidence regarding the cardiovascular effects of incretin‐based medications. GLP‐1 receptor agonists (GLP‐1RAs) have demonstrated protective effects in preclinical models. Clinical trials show modest but consistent reductions in major adverse cardiovascular events (MACE), with additional renal benefits. Conversely, DPP‐4 inhibitors display cardiovascular neutrality. Real‐world studies largely support the superiority of GLP‐1RAs over other glucose‐lowering agents (e.g. DPP‐4 inhibitors, insulin) in reducing MACE, though their benefits in heart failure (HF) with reduced ejection fraction remain limited. Recent trials in patients with obesity‐related HFpEF demonstrate that GLP‐1RAs and dual GIP/GLP‐1 agonists significantly improve symptoms, functional status, and reduce HF events.

Conclusions

While incretin therapies represent a transformative advancement in cardiometabolic care, challenges remain—including gastrointestinal side effects, adherence issues, lean mass loss and cost. As next‐generation agents (e.g. triple agonists) advance, lifestyle interventions remain essential for durable, management of diabetes, obesity and associated cardiovascular conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2IncretinsObesityHypoglycemic AgentsCardiovascular DiseasesHumansDipeptidyl-Peptidase IV InhibitorsHeart FailureGlucagon-Like Peptide-1 Receptor AgonistsGlycemic ControlGastric Inhibitory Polypeptide

Stichwörter der Autor:innen

GLP‐1 receptor agonistscardiovascular outcome trialsdiabetesheart failure

Substanzen

IncretinsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • School of Medicine, University of Padova, Padova, Italy.

ORCID-Profile: Angelo Avogaro

Zitieren

APA

Avogaro, A. (2026). Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70184

Vancouver

Avogaro A. Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70184

BibTeX
@article{Avogaro2026,
  author = {Avogaro, Angelo},
  title = {Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1111/eci.70184}
}
Kostenlos starten →